Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Apple Restores Telegram to App Store After Content Policy Violation 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
CANTON, Mass., March 16, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March:
- The Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21st at 9:10 a.m. ET in New York City
- The Needham 17th Annual Healthcare Conference on Wednesday, March 28th at 10:30 a.m. ET in New York City
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
